EHAVE, Inc. (EHVVF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EHAVE, Inc. (EHVVF) trades at $0.00 with AI Score 45/100 (Grade C). EHAVE, Inc. is a healthcare technology company focused on developing medical psychedelics and a mental health data platform. Market cap: $287,657, Sector: Technology.
Last analyzed: Mar 16, 2026Analyst Coverage for EHVVF: EHVVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EHVVF against Technology peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EHVVF: the 1 perspectives are evenly split.
EHAVE, Inc. (EHVVF) Technology Profile & Competitive Position
EHAVE, Inc. develops medical psychedelics and a mental health data platform, integrating proprietary and third-party digital applications. Targeting clinicians, patients, and researchers, the company offers tools like MegaTeam and Ehave Dashboard. Based in Miami, Florida, EHAVE aims to enhance mental healthcare through data-driven insights and blockchain technology.
What Is the Investment Thesis for EHVVF?
EHAVE, Inc. presents a speculative investment opportunity within the emerging medical psychedelics and mental health technology sector. The company's focus on developing a comprehensive mental health data platform, integrating digital applications, and utilizing blockchain technology positions it to capitalize on the growing demand for innovative mental healthcare solutions. However, with a market capitalization of $0.00B and negative P/E ratio of -0.17, the company's financial performance and valuation require careful consideration. Key growth catalysts include the expansion of its product offerings, strategic partnerships with healthcare providers and pharmaceutical companies, and regulatory advancements in the medical psychedelics space. The company's ability to successfully commercialize its technology solutions and achieve profitability will be critical in driving long-term shareholder value. The negative beta of -0.19 suggests the stock moves contrary to the market, which may offer diversification benefits but also reflects potential investor uncertainty.
Based on FMP financials and quantitative analysis
EHVVF Key Highlights
- EHAVE, Inc. operates in the healthcare technology sector, focusing on medical psychedelics and mental health data platforms.
- The company's key products include MegaTeam, Ninja Reflex, and Ehave Dashboard, offering digital assessment and rehabilitation tools.
- EHAVE's mental health informatics platform utilizes blockchain technology to provide data-driven insights for clinicians.
- The company targets clinicians, patients, researchers, pharmaceutical companies, and payors with its technology solutions.
- EHAVE, Inc. has a market capitalization of $0.00B and a negative P/E ratio of -0.17, reflecting its early-stage growth profile.
Who Are EHVVF's Competitors?
EHVVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DFTC Defentect Group, Inc. | $0.09 | +14.13% | $7.12M | 45 |
| NOW ServiceNow, Inc. | $102.15 | -0.90% | 106B | 71 |
| RSASF RESAAS Services Inc. | $0.30 | -9.09% | $25.21M | 69 |
| PDFS PDF Solutions, Inc. | $64.14 | +0.45% | 3B | 68 |
| CSAI Cloudastructure Inc. | $0.36 | +0.85% | $6.72M | 68 |
| VERB Verb Technology Company, Inc. | $14.50 | +2.76% | $877.81M | 63 |
| RCT RedCloud Holdings plc | $0.66 | +2.79% | $29.56M | 63 |
| JAXAF Vinyl Group Ltd | $0.05 | +0.00% | $71.69M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EHVVF's Key Strengths?
- Proprietary mental health data platform and digital applications.
- Focus on integrating medical psychedelics and blockchain technology.
- Strategic partnerships with healthcare providers and pharmaceutical companies.
- Experienced management team with expertise in healthcare and technology.
What Are EHVVF's Weaknesses?
- Limited financial resources and operating history.
- Dependence on regulatory approvals for medical psychedelics.
- Intense competition in the healthcare technology sector.
- Small number of employees.
What Could Drive EHVVF Stock Higher?
- Potential regulatory approvals for medical psychedelics in key markets.
- Launch of new digital applications and therapeutic solutions.
- Expansion of strategic partnerships with healthcare providers and pharmaceutical companies.
- Increasing adoption of Ehave Dashboard by clinicians and healthcare organizations.
- Growing awareness of mental health issues and demand for innovative solutions.
What Are the Key Risks for EHVVF?
- Regulatory hurdles and changing healthcare policies.
- Technological obsolescence and cybersecurity risks.
- Economic downturn and reduced healthcare spending.
- Competition from larger and more established companies.
- Dependence on key personnel and strategic partnerships.
What Are the Growth Opportunities for EHVVF?
- Expansion of Product Offerings: EHAVE can expand its product offerings by developing new digital applications and therapeutic solutions tailored to specific mental health conditions. The market for specialized mental health apps is growing rapidly, with an estimated market size of $10 billion by 2028. By introducing innovative products that address unmet needs, EHAVE can attract new customers and increase its market share. This expansion can be achieved through internal development efforts, strategic acquisitions, or partnerships with other technology companies. The timeline for launching new products is estimated to be within the next 1-3 years.
- Strategic Partnerships: EHAVE can form strategic partnerships with healthcare providers, pharmaceutical companies, and research institutions to expand its reach and accelerate the adoption of its technology solutions. Collaborating with established players in the healthcare industry can provide EHAVE with access to new markets, distribution channels, and expertise. For example, partnering with a large hospital network could enable EHAVE to integrate its platform into the hospital's existing infrastructure, providing clinicians with seamless access to its tools. These partnerships can be established within the next 6-12 months.
- Regulatory Advancements in Medical Psychedelics: EHAVE can capitalize on regulatory advancements in the medical psychedelics space to develop and commercialize psychedelic-assisted therapies. As regulations surrounding psychedelics become more favorable, EHAVE can leverage its expertise in digital health and data analytics to create innovative treatment protocols and monitoring tools. The market for psychedelic-assisted therapies is projected to reach $5 billion by 2030. EHAVE can position itself as a leader in this emerging field by conducting clinical trials, obtaining regulatory approvals, and establishing partnerships with psychedelic research organizations. This opportunity is contingent on regulatory changes that are expected to occur over the next 3-5 years.
- Geographic Expansion: EHAVE can expand its geographic presence by entering new markets in North America and Europe. The demand for mental health solutions is growing globally, presenting significant opportunities for EHAVE to expand its customer base and increase its revenue. By adapting its platform to meet the specific needs of different markets, EHAVE can attract new customers and establish a strong foothold in key regions. The timeline for geographic expansion is estimated to be within the next 2-4 years, focusing on markets with favorable regulatory environments and high demand for mental health services.
- Data Monetization: EHAVE can explore opportunities to monetize its data assets by providing anonymized and aggregated data to pharmaceutical companies, research institutions, and other healthcare organizations. The market for healthcare data is growing rapidly, with an estimated market size of $25 billion by 2027. By leveraging its expertise in data analytics and blockchain technology, EHAVE can create valuable data products that address the needs of its customers. This can be achieved by establishing data sharing agreements, developing data analytics tools, and ensuring compliance with privacy regulations. The timeline for data monetization initiatives is estimated to be within the next 1-2 years.
What Opportunities Does EHVVF Have?
- Expansion of product offerings and geographic presence.
- Increasing demand for mental health solutions and personalized care.
- Growing acceptance of medical psychedelics as a treatment option.
- Potential for data monetization and strategic acquisitions.
What Threats Does EHVVF Face?
- Regulatory hurdles and changing healthcare policies.
- Technological obsolescence and cybersecurity risks.
- Economic downturn and reduced healthcare spending.
- Competition from larger and more established companies.
What Are EHVVF's Competitive Advantages?
- Proprietary Technology: EHAVE's mental health data platform and digital applications are protected by patents and trade secrets.
- Data Network Effects: As more clinicians and patients use EHAVE's platform, the value of its data increases, creating a network effect.
- Strategic Partnerships: EHAVE's partnerships with healthcare providers and pharmaceutical companies provide access to new markets and expertise.
- First-Mover Advantage: EHAVE is an early mover in the emerging medical psychedelics and mental health technology space.
What Does EHVVF Do?
Incorporated in 2011 and based in Miami, Florida, EHAVE, Inc. operates as a healthcare technology company focused on developing medical psychedelics and a mental health data platform. The company's core mission revolves around integrating proprietary and third-party assessment and therapeutic digital applications to improve mental healthcare delivery in Canada. EHAVE offers a suite of technology solutions designed for various stakeholders, including clinicians, patients, researchers, pharmaceutical companies, and payors. Key products include MegaTeam and Ninja Reflex, clinically validated digital assessment and rehabilitation software designed to enhance patient engagement and data modeling. These tools are adapted from custom and third-party sources to provide comprehensive support. The Ehave Dashboard, a mental health informatics platform, allows clinicians to make objective and intelligent decisions through data insight using blockchain technology. This platform facilitates data-driven decision-making by providing clinicians with actionable insights derived from patient data. EHAVE also provides a platform for medical practitioners to administer healthcare services to patients at home, expanding access to care and improving patient outcomes. The company's solutions are designed to streamline workflows, improve data accuracy, and enhance the overall quality of mental healthcare services.
What Products and Services Does EHVVF Offer?
- Develops medical psychedelics and mental health data platforms.
- Integrates proprietary and third-party assessment and therapeutic digital applications.
- Offers MegaTeam and Ninja Reflex, clinically validated digital assessment and rehabilitation software.
- Adapts custom and third-party clinically validated digital assessment and rehabilitation software.
- Provides Ehave Dashboard, a mental health informatics platform using blockchain technology.
- Offers a platform for medical practitioners to administer healthcare services to patients at home.
- Provides technology solutions to clinicians, patients, researchers, pharmaceutical companies, and payors.
How Does EHVVF Make Money?
- Develops and licenses its proprietary mental health data platform and digital applications.
- Generates revenue through subscriptions and usage fees from clinicians, patients, and healthcare organizations.
- Partners with pharmaceutical companies and research institutions to provide data analytics and insights.
- Offers customized solutions and consulting services to meet the specific needs of its customers.
What Industry Does EHVVF Operate In?
EHAVE, Inc. operates within the rapidly evolving healthcare technology sector, specifically targeting the mental health market. The industry is experiencing significant growth driven by increasing awareness of mental health issues, technological advancements, and a shift towards personalized and data-driven care. The market for mental health solutions is estimated to reach billions of dollars in the coming years, presenting substantial opportunities for companies like EHAVE. Competitors include companies like ANDI, CAVR, CGUD, DFTC, and DVNCF, which are also developing digital health solutions. EHAVE's focus on integrating medical psychedelics and blockchain technology differentiates it within this competitive landscape.
Who Are EHVVF's Key Customers?
- Clinicians: Mental health professionals who use EHAVE's platform to assess and treat patients.
- Patients: Individuals seeking mental health support and utilizing EHAVE's digital applications.
- Researchers: Academic and clinical researchers who leverage EHAVE's data and tools for mental health studies.
- Pharmaceutical Companies: Companies developing and marketing mental health medications and therapies.
EHVVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in the growth potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to mental health solutions.
- Increased engagement on social media platforms indicates a growing interest and support for the company's initiatives and products.
- Recent partnerships and collaborations have sparked optimism about expanding market reach and enhancing service offerings.
Bear Case
- Concerns about regulatory hurdles in the mental health sector have created uncertainty among investors regarding future operations.
- Negative sentiment has emerged in some community discussions, focusing on the company's ability to execute its business model effectively.
- Recent earnings reports have raised questions about profitability and operational efficiency, causing skepticism among traders.
- Market perception remains cautious, with analysts pointing to broader economic factors that could impact the company's growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EHVVF Latest News
-
AIBotics Enters Strategic AI Partnership and Joint Venture with ARYA AI Labs to Advance Next-Generation Deterministic “World Models”
globenewswire.com · May 19, 2026
-
Google Partner NovaCore Labs and AIBotics Advance Acquisition and Expand Robot Deployment Across Jamaica
Yahoo! Finance: EHVVF News · Apr 30, 2026
-
AIBotics Crosses the Line from Concept to Cash Flow as 3DX Industries Commits to PHILL™ Production
Yahoo! Finance: EHVVF News · Apr 27, 2026
-
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
· Oct 18, 2021
EHVVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EHVVF.
Price Targets
Wall Street price target analysis for EHVVF.
EHVVF MoonshotScore
What does this score mean?
The MoonshotScore rates EHVVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
AIBotics Enters Strategic AI Partnership and Joint Venture with ARYA AI Labs to Advance Next-Generation Deterministic “World Models”
Google Partner NovaCore Labs and AIBotics Advance Acquisition and Expand Robot Deployment Across Jamaica
AIBotics Crosses the Line from Concept to Cash Flow as 3DX Industries Commits to PHILL™ Production
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Leadership: Benjamin Kaplan
CEO
Benjamin Kaplan serves as the CEO of EHAVE, Inc. His background includes experience in managing early-stage companies and navigating the complexities of the healthcare technology sector. Kaplan's expertise lies in strategic planning, business development, and capital raising. He has a proven track record of building and scaling innovative companies in emerging markets. His leadership is focused on driving growth, fostering innovation, and creating value for shareholders.
Track Record: Under Benjamin Kaplan's leadership, EHAVE, Inc. has focused on developing its mental health data platform and expanding its product offerings. Key milestones include the launch of the Ehave Dashboard and the establishment of strategic partnerships with healthcare providers. Kaplan has also overseen the company's efforts to navigate the regulatory landscape for medical psychedelics and position EHAVE as a leader in this emerging field. Given the limited information available, a comprehensive assessment of his long-term track record is challenging.
EHVVF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that EHAVE, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can increase the risk of fraud and manipulation. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The unknown disclosure status makes it difficult to assess the company's financial health and performance.
- Low Liquidity: The stock may experience low trading volumes and wide bid-ask spreads, increasing transaction costs and price volatility.
- Regulatory Uncertainty: OTC stocks face fewer regulatory requirements, increasing the risk of fraud and manipulation.
- Speculative Nature: EHAVE, Inc.'s focus on medical psychedelics and mental health technology is highly speculative and subject to regulatory risks.
- Limited Operating History: The company has a limited operating history and may face challenges in scaling its business and achieving profitability.
- Verify the company's registration and compliance with regulatory requirements.
- Obtain and review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Research the company's legal and regulatory risks.
- Understand the company's capital structure and funding sources.
- Monitor news and developments related to the company and its industry.
- Focus on developing medical psychedelics and mental health data platforms.
- Integration of proprietary and third-party digital applications.
- Partnerships with healthcare providers and research institutions.
- Development of Ehave Dashboard, a mental health informatics platform using blockchain technology.
- Experienced management team with expertise in healthcare and technology.
What Investors Ask About EHAVE, Inc. (EHVVF) — Technology
What does EHAVE, Inc. do?
EHAVE, Inc. is a healthcare technology company that develops medical psychedelics and a mental health data platform. The company integrates proprietary and third-party assessment and therapeutic digital applications to improve mental healthcare delivery. Its key products include MegaTeam, Ninja Reflex, and Ehave Dashboard. These solutions target clinicians, patients, researchers, pharmaceutical companies, and payors, aiming to enhance patient engagement, data modeling, and data-driven decision-making in the mental health sector. The company also provides a platform for medical practitioners to administer healthcare services to patients at home.
What do analysts say about EHVVF stock?
There is currently no available analyst coverage for EHVVF stock. Given its OTC listing and small market capitalization, the stock is unlikely to be actively followed by major investment banks or research firms. Investors should conduct their own independent research and due diligence before investing in EHVVF. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, should be compared to those of its peers in the healthcare technology sector. Growth considerations include the company's ability to commercialize its technology solutions, expand its customer base, and achieve profitability.
What are the main risks for EHVVF?
The main risks for EHVVF include regulatory hurdles in the medical psychedelics space, technological obsolescence, competition from larger companies, and limited financial resources. The company's success depends on obtaining regulatory approvals for its products and services, which is subject to uncertainty and delays. The healthcare technology sector is rapidly evolving, requiring EHAVE to continuously innovate and adapt to changing market conditions. Competition from larger and more established companies with greater resources poses a significant threat. The company's limited financial resources may constrain its ability to invest in research and development, marketing, and sales.
How does EHAVE, Inc. invest in research and development?
Information on EHAVE, Inc.'s specific R&D spending as a percentage of revenue and key innovation areas is not available. However, as a technology company focused on developing medical psychedelics and mental health data platforms, R&D is likely a critical component of its operations. EHAVE likely invests in developing new digital applications, therapeutic solutions, and data analytics tools. The company's patent portfolio and clinical trial activities, if any, would provide further insights into its R&D efforts. Investors should monitor the company's announcements and filings for updates on its R&D initiatives.
What are the growth drivers for EHVVF stock?
EHAVE, Inc.'s primary growth catalysts include the expansion of its product offerings, strategic partnerships with healthcare providers and pharmaceutical companies, and regulatory advancements in the medical psychedelics space. The company's ability to successfully commercialize its technology solutions and achieve profitability will be critical in driving long-term shareholder value. The increasing demand for mental health solutions and personalized care also presents a significant growth opportunity. EHAVE's focus on integrating medical psychedelics and blockchain technology differentiates it within the competitive landscape and positions it to capitalize on emerging trends.
What are the key factors to evaluate for EHVVF?
EHAVE, Inc. (EHVVF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does EHVVF data refresh on this page?
EHVVF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EHVVF's recent stock price performance?
EHAVE, Inc. (EHVVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary mental health data platform and digital applications. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC status and lack of analyst coverage.
- Financial data is based on available information and may not be comprehensive.
- AI analysis is pending for EHVVF.